<div id="readability-page-1" class="page"><div><p>Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings.</p><p>  For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million.</p><p>  The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025.</p><p>  Perella Weinberg Partners and Piper Sandler served as OrganOx?s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham &amp; Watkins acted as legal counsel to OrganOx in this transaction.</p><p>Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 30, 2025.</p></div></div>

4543

<p>泰尔默公司已完成对 OrganOx Limited 99.5% 股份的收购，交易金额为 15 亿美元，使其成为全资子公司。该交易于 2025 年 10 月 30 日最终达成，资金来源为现金和借款。OrganOx 在截至 2024 年 12 月 31 日的年度报告中，总收入为 6914 万美元，息税前利润为 901 万美元。此次交易由 Perella Weinberg Partners 和 Piper Sandler 提供顾问服务，法律顾问为 Latham & Watkins</p>

泰尔茂公司已完成从一组股东手中收购 OrganOx 有限公司剩余 99.5% 股份的交易